Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma
Hongyan Xu,Wenjing Wang,Junlei Yin,Chengcun Song,Lin Li,Zhi Sun
DOI: https://doi.org/10.2147/DDDT.S388777
2022-12-14
Abstract:Hongyan Xu, Wenjing Wang, Junlei Yin, Chengcun Song, Lin Li, Zhi Sun Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, People's Republic of China Correspondence: Hongyan Xu, Department of Chemotherapy, Weihai Municipal Hospital, No. 248, Tongyi Road, Huancui District, Weihai, Shangdong, 264200, People's Republic of China, Tel +860631-5287510, Email Aim: To investigate the efficacy and safety of preoperative neoadjuvant therapy (PD-1 inhibitor plus nab-PTX and nedaplatin) for resectable stage III lung squamous cell carcinoma (SCC) patients. Methods: Patients with locally advanced lung SCC (stage IIIA, IIIB) who received PD-1 inhibitor combined with nab-PTX and NED between February 2019 and June 2021 in Weihai Municipal Hospital were included and underwent surgical treatment 4 weeks after 2– 4 cycles neoadjuvant therapy. The rate of resection R0, the effective rate, the complete pathological remission rate (pCR) and the rate of major pathological remission (MPR) were observed. Results: A total of 14 initially unresectable male patients with lung SCC were included and received neoadjuvant treatment after evaluation. Nine out of 14 patients (64.3%) experienced treatment-related adverse events (TRAE), among which 8 (57.1%) experienced grade (G) I–II TRAEs including nausea, vomiting, fatigue, constipation, elevated ALT and AST, hyperthyroidism, hypothyroidism, rash, granulocytopenia, and thrombocytopenia, and 1 (7.1%) experienced grade III–V TRAEs (G), including granulocytopenia and atelectasis. Thirteen patients (92.86%) achieved RECIST-assessed partial remission (PR), while 1 patient (7.14%) achieved stable disease (SD) on imaging assessment after neoadjuvant treatment and continued to be progression-free for 26 months. Of the 11 patients who underwent resection, all were alive and recurrence/progression-free. MPR and pCR were observed in 2 (18.18%) and 9 (81.82%), respectively. IHC results exhibited that all NSCLC patients exhibited positive PD-L1 expression (9/14, TPS ≥ 50% or greater; 5/14, 1% < TPS < 50%). Two were negative for ALK, EGFR, and ros-1, and the rest were not examined for driver oncogene mutation. Conclusion: The neoadjuvant therapy of the PD-1 inhibitor combined with nab-PTX and NED demonstrated remarkable therapeutic efficacy and good safety on stage III lung SCC without increasing the risk of TRAE, mortality and surgery-related complications, or impede surgery feasibility. Keywords: lung squamous cell lung cancer, neoadjuvant therapy, immunotherapy, complete pathological remission, pCR, major pathological remission, MPR Lung cancer is one of the most common malignancies and has the highest rate of cancer-related death. 1 Approximately 1.5 million new cases of lung cancer are diagnosed annually worldwide, of which approximately 80–85% are non-small-cell lung cancers (NSCLCs). 2,3 Surgery is considered the ideal option for treatment, but only about 20–25% of NSCLCs are suitable for potentially curative resection, the majority of which were at stage I–IIIA and only a few were at stage III B. 4–6 NSCLC has several types of pathologies, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, etc., among which lung squamous cell carcinoma is the second common subtype of NSCLC, accounting for approximately 20–30% of NSCLC and exhibiting distinctive histological and genetic characteristics. Surgical resection is often difficult, especially for stage III lesions. Neoadjuvant therapy is a promising approach to increase the chance of curative rates and improve long-term survival for patients with locally advanced-stage lung squamous cell carcinoma. It has been applied before surgery to achieve the purpose of tumor regression, increased ratio of R0 resection, and elimination of micrometastases, which finally benefits patient overall survival. Since nivolumab, the first immune checkpoint inhibitor (ICI), was approved as a second-line treatment in China for NSCLC in 2018, ICIs have played an increasingly important role in the treatment of NSCLCs without driver gene mutations. 7 ICIs alone or in combination with chemotherapy have become the standard regimen for first-line, second-line, and post-line treatment of NSCLCs. 8–12 Recently, neoadjuvant treatment for locally advanced lung squamous cell carcinoma with immunochemotherapy has been explored. In this study, our objective was to explore the feasibility and safety of the programmed cell death 1 (PD-1) inhibitor combined with nanoparticle albumin-bound paclitaxel (nab-PTX) and nedaplatin (NED) in preoperative neoadjuvant therapy for patients with unresectable stage III lung squamous cell carcinoma. It was a single-centered retrospe -Abstract Truncated-